Downstream Processing: Platform Technology for Developing Purification Processes - - BioPharm International


Downstream Processing: Platform Technology for Developing Purification Processes

BioPharm International
Volume 20, Issue 3

Figure 8B
The results in Figure 8A clearly show the effects of the main parameters—pH,conductivity, salt—in the loading (elution) phase over a broad range around the standard operating ranges. The outcome of these studies can be used to set or restrain limits for certain critical parameters that may influence or become critical in this specific purification step. Moreover, optimization in terms of interaction effects, as shown in Figure 8B (interaction between pH in loading phase and conductivity in the elution phase) indicate that not only are the main parameters important, but their interactions are, too.

Finally, this platform technology shows that a structural approach for setting up a downstream process (for each purification step) is feasible. Speed, understanding, and robustness may aid in the use of this platform technology as a very useful approach for every downstream process in development.

Michel Eppink is director of the downstream processing methodology and troubleshooting section of the API/biotech division at NV Organon, Oss, The Netherlands, +31 412 665850,
. Rick Schreurs is group leader of the section, and Anke Gijsen and Kees Verhoeven are research technicians.


1. Frost & Sullivan. Strategic analysis of world downstream processing markets in biopharmaceutical production. 2004

2. Wang T, John S, Archuleta S, Jonsson CB. Rapid, high-throughput purification of HIV-1 integrase using microtiter plate technology, Protein Expres & Purif 2004;33:232–37.

3. Eeckhout D, De Clercq A, Van de Slijke E, Van Leene J, Sals H, Casteels P, et al. A technology platform for the fast production of monoclonal recombinant antibodies against plant proteins and peptides. J Immunol Methods 2004;294:181–7.

4. Merchant M, Weinberger SR. Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 2000;21: 1164–77

5. Weinberger SR, Viner RI, Ho P. Tagless extraction-retentate chromatography: A new global protein digestion strategy for monitoring differential protein expression. Electrophoresis 2002;23:3182–92.

6. Seibert V, Ebert MPA, Buschmann T. Advances in clinical cancer proteomics: SELDI–T–of-mass spectrometry and biomarker discovery. Br Funct Genomics and Proteomics 2005;4:16–26.

7. Seibert V, Wiesner A, Buschmann T, Meuer J. Surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI TOF–MS) and ProteinChip technology in proteomics research. Pathol Res Pract 2004;200:83–94.

8. Montgomery DC. Design and Analysis of Experiments. New York, NY: Wiley & Sons, Inc; 2001.

blog comments powered by Disqus



NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
FDA and NIH Win Award for IP Licensing of Meningitis Vaccine
September 26, 2014
Author Guidelines
Source: BioPharm International,
Click here